Angelchem Nutraceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-12-2024
- Paid Up Capital ₹ 0.10 M
as on 15-12-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.36 Cr
as on 15-12-2024
- Revenue 218.75%
(FY 2022)
- Profit 579.26%
(FY 2022)
- Ebitda 1025.67%
(FY 2022)
- Net Worth 285.54%
(FY 2022)
- Total Assets 67.36%
(FY 2022)
About Angelchem Nutraceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.36 Cr.
Amar Dhumal and Priya Dhumal serve as directors at the Company.
- CIN/LLPIN
U24100PN2019PTC182524
- Company No.
182524
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Feb 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Angelchem Nutraceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amar Dhumal  | Director | 27-Feb-2019 | Current |
| Priya Dhumal | Director | 27-Feb-2019 | Current |
Financial Performance of Angelchem Nutraceuticals.
Angelchem Nutraceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 218.75% increase. The company also saw a substantial improvement in profitability, with a 579.26% increase in profit. The company's net worth Soared by an impressive increase of 285.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Angelchem Nutraceuticals?
Unlock access to Angelchem Nutraceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Alpinist Pharmaceuticals Private LimitedActive 2 years 7 months
Amar Dhumal and Priya Dhumal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 18 Nov 2023 | ₹6.80 M | Open |
Others Creation Date: 23 Jan 2023 | ₹6.80 M | Open |
How Many Employees Work at Angelchem Nutraceuticals?
Unlock and access historical data on people associated with Angelchem Nutraceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Angelchem Nutraceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Angelchem Nutraceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
